Applications of 3-Morpholino-2-Hydroxypropanesulfonic Acid Sodium Salt in Industrial Manufacturing

This page outlines specific industrial applications for 3-Morpholino-2-Hydroxypropanesulfonic Acid Sodium Salt based on proven downstream practices. Each section details sector compliance requirements, recommended dosage, stage of process incorporation, and principal finished goods produced by end users.

1. Biopharmaceutical Buffer Systems

Manufacturers in bioprocessing and diagnostic reagent sectors use this compound as a Good’s buffer, capitalizing on its narrow pH stability (6.8–7.2) for sensitive protein purification processes, cell culture media preparation, and in-phase buffer solutions for analytic chromatography. Its minimal interaction with biologic molecules ensures consistent results in upstream and downstream harvesting of monoclonal antibodies and recombinant proteins. Integrators leverage its low toxicity and strong ionic strength control, particularly where regulatory and purity demands restrict buffer choices.

Industry compliance standards

• ICH Q7 GMP Guidelines
• USP <1043> Ancillary Materials for Cell, Gene, and Tissue-Engineered Products
• 21 CFR 211.65 Clean Rooms and Controlled Environments for Sterile Drug Production
• ISO 13485 for Diagnostic Reagent Manufacturing

Typical usage ratio

• Final buffer concentrations range from 10–50 mmol/L, adjusted to maintain target pH per bioprocess scale and protein species. Dose selection follows process-specific titration curves after QC titration and osmolality adjustment.

Downstream process integration

• Direct dissolution into WFI (Water for Injection) during media and buffer preparation
• Incorporated during equilibration, wash, and elution phases in chromatography columns
• Formulated in lyophilized diagnostic kit blend prior to terminal sterilization

Final product types

• Monoclonal antibody APIs
• Cell culture supplements for vaccine production
• IVD reagent kits
• Pre-filled sterile buffer solutions

2. Molecular Biology and Genomics Workflows

Companies manufacturing reagents for PCR, qPCR, enzymatic digestion, and next-generation sequencing utilize this buffer to optimize DNA/RNA stabilization and enzyme kinetics. Its negligible absorbance at 260/280 nm eliminates background signal during nucleic acid quantification. Process control teams value its chemical inertness, reducing variability across gene expression profiling assays for pharma research laboratories and genomics service providers.

Industry compliance standards

• ISO 9001:2015 Quality Management Systems
• ISO 18385:2016 Minimizing the Risk of Human DNA Contamination in Non-IVD Forensics Labs
• US Pharmacopeia <1024> Nucleic Acid Reagents (for Research Use Only products)

Typical usage ratio

• Buffer formulations typically employ 20–40 mM, with concentration selected based on enzyme supplier protocol and magnesium ion dependency; pre-validation includes melt curve adjustment for PCR specificity.

Downstream process integration

• Primer reconstitution and master mix preparation
• Pre-aliquotted buffer bases for high-throughput robotics liquid handling
• Sealing and stabilization of prepared DNA/RNA eluates pre-sequencing

Final product types

• Ready-to-use PCR/qPCR kits
• DNA/RNA extraction and stabilization kits
• Library preparation buffers for sequencing platforms
• Custom enzyme reaction mixes for genotyping

3. Cell and Tissue Culture Medium Preparation

In advanced biomanufacturing, this buffering agent helps maintain physiological pH in complex cell and tissue culture media, contributing to precise environmental control. Particularly in adherent and suspension mammalian cell lines, formulators choose this compound to reduce pH drift during extended batch and perfusion runs. Its low metal chelation and biocompatibility profile align well with serum-free and chemically defined media systems where extraneous ions or byproducts could confound cell growth performance analysis.

Industry compliance standards

• USP <1043> Ancillary Materials for Biopharmaceutical Manufacturing
• 21 CFR Part 820 cGMP for Medical Device and Diagnostic Production
• ISO 14644 Cleanroom Standards for Tissue Engineering Facilities
• Ph. Eur. 5.2.12 for Cell-based Medicinal Products

Typical usage ratio

• Standard working concentrations fall within 10–30 mM, modulated according to baseline medium composition, with higher doses for high-density cultures; dose verified during pilot runs for buffering capacity retention.

Downstream process integration

• Post-sterile filtration blending to avoid precipitation with medium constituents
• Bulk mixing tanks during initial basal medium preparation
• Subcomponent addition to serum-free, chemically defined, or animal component-free media formulations

Final product types

• Cell therapy and regenerative medicine media
• Commercial cell banking reagents
• High-performance serum-free supplements
• Tissue engineering scaffold culture media

4. In Vitro Diagnostic (IVD) and Clinical Test Kit Manufacturing

IVD manufacturers incorporate this buffering agent in the formulation of blood analysis reagents, enzyme-linked immunosorbent assay (ELISA) buffers, and point-of-care clinical chemistry kits. The material’s ability to provide stable pH and ionic strength supports consistent assay reproducibility, a critical control point during quality release testing. Regulatory inspection teams require documentation of trace impurities since buffer-related variability can affect measured clinical parameters, especially in quantitative serological and biochemical assays.

Industry compliance standards

• ISO 13485 for Medical Device Quality Management
• 21 CFR 820.70 for IVD Manufacturing Controls
• IVDR (EU) 2017/746 for Conformity in Clinical Use
• CLSI EP17-A2 for Limit of Detection Testing

Typical usage ratio

• Buffer inclusion typically ranges from 15–25 mM in finished reagent mixes, optimized for each assay’s required pH/ionic balance, batch consistency controlled through routine assay calibration curves and spike recovery experiments.

Downstream process integration

• Bulk tank mixing during premix buffer production
• Formulation with antibody or antigen storage matrices pre-filling
• Integration into lyophilized microtiter plate reagents for ELISA

Final product types

• Blood chemistry analysis kits
• Serology and immunoassay test kits
• Polymer-based lateral flow devices
• Pre-made buffer vials for point-of-care devices

5. Protein Electrophoresis and Analytical Chromatography

Analytical laboratories and contract research facilities routinely select this buffering material as a running buffer for polyacrylamide gel electrophoresis (PAGE) and as a mobile phase modifier for HPLC and ion-exchange chromatography. Its compatibility with UV detection systems and low background interference assist QC teams during purity profiling and analytical validation. The buffering agent’s chemical structure provides stable buffering near neutral pH, minimizing protein denaturation and preserving reproducibility for regulatory submissions and reference standard preparations.

Industry compliance standards

• USP <1010> Analytical Data Standards
• OECD GLP Principles for Chemicals Testing
• 21 CFR Part 58 GLP for Nonclinical Laboratory Studies
• ISO/IEC 17025 Analytical Testing Laboratories

Typical usage ratio

• 20–50 mM as a running buffer for PAGE, and 5–30 mM in chromatographic mobile phases; determined by sample type and method-specific buffer screening studies with validation of signal baseline and retention time stability.

Downstream process integration

• Gel buffer mixing post-polymerization to prevent precipitation with initiators
• Preparation of mobile phases in analytical testing for release specification
• Reconstitution of lyophilized reference standards for comparability testing

Final product types

• Pre-cast electrophoresis buffer kits
• HPLC and ion-exchange column buffer solutions
• Analytical reference standards
• Bioanalytical method validation packs